RA0359

antibody from Oursmab

Targeting: IL1RL1 DER4, FIT-1, IL33R, ST2, ST2L, ST2V, T1

Western blot (Supportive data in Antibodypedia)

ELISA (Supportive data in Antibodypedia)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0359

Provider

Oursmab

Product name

Astegolimab (Biosimilar Reference Antibody) (IL1RL1)

Antibody type

Monoclonal

Description

Astegolimab is a humanized IgG2 monoclonal antibody designed as a specific inhibitor of the interleukin-33 receptor (ST2). It functions by selectively binding to the ST2 subunit (IL1RL1), thereby blocking the binding of its cytokine ligand, interleukin-33 (IL-33). This blockade prevents IL-33/ST2 signaling, a key pathway in type 2 and epithelial-derived inflammation. Astegolimab is in clinical development for the treatment of chronic obstructive pulmonary disease (COPD) and asthma, with Phase II trials demonstrating positive results in reducing exacerbations in COPD patients with a history of exacerbations.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

Western blot

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

Astegolimab (Biosimilar Reference Antibody) (IL1RL1)-RA0359-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.

ELISA

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

ELISA plate pre-coated Antigen protein, can bind Astegolimab (Biosimilar Reference Antibody) (IL1RL1)-RA0359 in a linear range of 15.63-125 ng/mL.